Polypharmacy and Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 10, 2005, Pages 1211-1216

  Cross, R K ^a,b,d   Wilson, K T ^a,b   Binion, D G ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Veterans Affairs   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMINOSALICYLIC ACID; ANALGESIC AGENT; AZATHIOPRINE; CALCIUM CARBONATE; DOCUSATE SODIUM; GASTROINTESTINAL AGENT; IRON; METRONIDAZOLE; MINERAL; MULTIVITAMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE DISTRIBUTION; ALGORITHM; CLINICAL FEATURE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; SIDE EFFECT;

ADULT; AGE FACTORS; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 19544382356     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02429.x     Document Type: Review

References (26)

1. Birketvedt GS, Berg KJ, Fausa O, et al. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. Inflamm Bowel Dis 2000; 6: 275-9.
2. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-9.
3. Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82.
4. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
5. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 835-40.
6. Korelitz BI, Zlatanic J, Goel F, et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol 1999; 28: 341-4.
7. Haber CJ, Meltzer SJ, Present DH, et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-6.
8. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 1730-4.
9. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
10. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14.
11. Puchner TC, Kugathasan S, Kelly KJ, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-7.
12. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107-16.
13. Veehof L, Stewart R, Haaijer-Ruskamp F, et al. The development of polypharmacy. A longitudinal study. Fam Pract 2000; 17: 261-7.
14. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325-9.
15. Thomas HF, Sweetnam PM, Janchawee B, et al. Polypharmacy among older men in South Wales. Eur J Clin Pharmacol 1999; 55: 411-5.
16. Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000; 56: 501-9.
17. Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55: 809-17.
18. Viktil KK, Enstad M, Kutschera J, et al. Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharm World Sci 2001; 23: 153-8.
19. Bjerrum L, Sogaard J, Hallas J, et al. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54: 197-202.
20. Perry BA, Turner LW. A prediction model for polypharmacy: are older, educated women more susceptible to an adverse drug event? J Women Aging 2001; 13: 39-51.
21. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9-15.
22. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999; 13: 65-73.
23. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol 2001; 96: 2921-8.
24. Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 382-8.
25. Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 697-701.
26. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-82.